Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Allogene Therapeutics (ALLO) Other Operating Expenses (2019 - 2025)

Allogene Therapeutics' Other Operating Expenses history spans 6 years, with the latest figure at $2.4 million for Q2 2025.

  • For Q2 2025, Other Operating Expenses fell 52.25% year-over-year to $2.4 million; the TTM value through Sep 2025 reached $2.4 million, down 91.78%, while the annual FY2024 figure was $15.7 million, 18.66% up from the prior year.
  • Other Operating Expenses for Q2 2025 was $2.4 million at Allogene Therapeutics, down from $10.7 million in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $13.2 million in Q4 2023 and bottomed at -$1000.0 in Q4 2021.
  • The 4-year median for Other Operating Expenses is $3.7 million (2024), against an average of $5.2 million.
  • The largest annual shift saw Other Operating Expenses soared 200.0% in 2021 before it plummeted 52.25% in 2025.
  • A 4-year view of Other Operating Expenses shows it stood at -$1000.0 in 2021, then skyrocketed by 1324600.0% to $13.2 million in 2023, then dropped by 19.0% to $10.7 million in 2024, then plummeted by 77.8% to $2.4 million in 2025.
  • Per Business Quant, the three most recent readings for ALLO's Other Operating Expenses are $2.4 million (Q2 2025), $10.7 million (Q3 2024), and $5.0 million (Q2 2024).